A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：0
作者：
Bewersdorf, Jan Philipp
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael J.
Rampal, Raajit
Bose, Prithviraj
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7086
引用
收藏
页数：1
相关论文
共 50 条
[41]   Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia [J].
Mora, Barbara ;
Giorgino, Toni ;
Guglielmelli, Paola ;
Rumi, Elisa ;
Maffioli, Margherita ;
Rambaldi, Alessandro ;
Caramella, Marianna ;
Komrokji, Rami ;
Gotlib, Jason ;
Kiladjian, Jean Jacques ;
Cervantes, Francisco ;
Devos, Timothy ;
Palandri, Francesca ;
De Stefano, Valerio ;
Ruggeri, Marco ;
Silver, Richard T. ;
Benevolo, Giulia ;
Albano, Francesco ;
Cavalloni, Chiara ;
Barraco, Daniela ;
Pietra, Daniela ;
Barbui, Tiziano ;
Rotunno, Giada ;
Vannucchi, Alessandro Maria ;
Passamonti, Francesco .
LEUKEMIA RESEARCH, 2018, 69 :100-102
[42]   CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY [J].
Mora, B. ;
Giorgino, T. ;
Guglielmelli, P. ;
Rumi, E. ;
Maffioli, M. ;
Caramazza, D. ;
Rambaldi, A. ;
Caramella, M. ;
Komrokji, R. ;
Gotlib, J. ;
Kiladjian, J. J. ;
Cervantes, F. ;
Devos, T. ;
Palandri, F. ;
De Stefano, V. ;
Ruggeri, M. ;
Silver, R. T. ;
Benevolo, G. ;
Albano, F. ;
Merli, M. ;
Pietra, D. ;
Casalone, R. ;
Barbui, T. ;
Rotunno, G. ;
Cazzola, M. ;
Vannucchi, A. M. ;
Passamonti, F. .
HAEMATOLOGICA, 2017, 102 :117-118
[43]   Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis [J].
Mesal, Ruben A. ;
Tefferi, Ayalew .
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) :471-479
[44]   Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF) [J].
Vargas, Pablo ;
Ovilla, Roberto ;
Alvarado, Martha ;
Lopez, Manuel ;
Hurtado Monroy, Rafael ;
Carlos Solis, Juan ;
Limon, Alejandro ;
Agreda, Gladys ;
Silva, Salvador ;
Julio Kassack, Juan ;
Zavala, Saida ;
Aguilar, Carlos ;
Baez, Enrique ;
Barrera, Esperanza ;
Osuna, Antonio ;
Morales, Javier ;
Herrera, Aquileo .
BLOOD, 2012, 120 (21)
[45]   TUMOR LYSIS SYNDROME IN POST-POLYCYTHEMIA VERA MYELOFIBROSIS AFTER RUXOLITINIB INITIATION [J].
Chopra, Nitin ;
Wu, Lesley ;
Leibrandt, Ryan ;
Rizk, Dahlia .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) :S603-S603
[46]   Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study [J].
Palandri, Francesca ;
Palumbo, Giuseppe A. ;
Iurlo, Alessandra ;
Polverelli, Nicola ;
Benevolo, Giulia ;
Breccia, Massimo ;
Abruzzese, Elisabetta ;
Tiribelli, Mario ;
Bonifacio, Massimiliano ;
Tieghi, Alessia ;
Isidori, Alessandro ;
Martino, Bruno ;
Sgherza, Nicola ;
D'Adda, Mariella ;
Bergamaschi, Micaela ;
Crugnola, Monica ;
Cavazzini, Francesco ;
Bosi, Costanza ;
Binotto, Gianni ;
Auteri, Giuseppe ;
Latagliata, Roberto ;
Ibatici, Adalberto ;
Scaffidi, Luigi ;
Penna, Domenico ;
Cattaneo, Daniele ;
Soci, Francesco ;
Trawinska, Malgorzata ;
Russo, Domenico ;
Cuneo, Antonio ;
Semenzato, Giampietro ;
Di Raimondo, Francesco ;
Aversa, Franco ;
Lemoli, Roberto M. ;
Heidel, Florian ;
Reggiani, Maria L. B. ;
Bartoletti, Daniela ;
Cavo, Michele ;
Catani, Lucia ;
Vianelli, Nicola .
SEMINARS IN HEMATOLOGY, 2018, 55 (04) :248-255
[47]   Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group [J].
Mora, Barbara ;
Guglielmelli, Paola ;
Rumi, Elisa ;
Maffioli, Margherita ;
Barraco, Daniela ;
Rambaldi, Alessandro ;
Caramella, Marianna ;
Komrokji, Rami S. ;
Kiladjian, Jean-Jacques ;
Gotlib, Jason ;
Iurlo, Alessandra ;
Cervantes, Francisco ;
Devos, Timothy ;
Palandri, Francesca ;
De Stefano, Valerio ;
Ruggeri, Marco ;
Silver, Richard T. ;
Albano, Francesco ;
Benevolo, Giulia ;
Cavalloni, Chiara ;
Uccella, Silvia ;
Accetta, Raffaella ;
Siracusa, Claudia ;
Agnoli, Stefania ;
Merli, Michele ;
Barbui, Tiziano ;
Bertu, Lorenza ;
Cazzola, Mario ;
Vannucchi, Alessandro M. ;
Passamonti, Francesco .
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (01) :E1-E3
[48]   Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population [J].
Xin Du ;
Daobin Zhou .
Frontiers of Medicine, 2016, 10 :437-443
[49]   Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population [J].
Xin Du ;
Daobin Zhou .
Frontiers of Medicine, 2016, 10 (04) :437-443
[50]   Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population [J].
Du, Xin ;
Zhou, Daobin .
FRONTIERS OF MEDICINE, 2016, 10 (04) :437-443
12345